The 1989 Nobel prize winner in Physiology/Medicine Prof. Varmus Harold E, Somwar R and others from High Throughput Screening Core Facility, and Organic Synthesis Core Facility, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA; and US National Cancer Institute, USA has published a research paper in the 27 September 2011 Proc Natl Acad Sci U S A. (I.F: >10) stating that “Superoxide dismutase 1 (SOD1) is a target for a small molecule identified in a screen for inhibitors of the growth of lung adenocarcinoma cell lines.”
Based on this this finding, Dr Boominathan, Founder Director-cum-chief scientist of GBMD, reports that: Molecular therapy for Human cancer: E6AP ubiquitin-protein ligase inhibits tumor cell proliferation via down regulation of Superoxide dismutase 1 (SOD1). This result suggests that E6AP, by decreasing the expression of its target gene, it may decrease the expression of SOD1. Thereby, it may increase the levels of Superoxide anions in cancer cells, which in turn may increase the expression of a number of tumor suppressor genes. Thus, pharmacological formulations encompassing “E6AP or its activators” may be used to treat human cancers.
To cite: Boominathan, Molecular therapy for Human cancer: E6AP ubiquitin-protein ligase inhibits tumor cell proliferation via down regulation of Superoxide dismutase 1 (SOD1), 03/October/2014, 11.08am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Courtesy: When you cite drop us a line at email@example.com
* Research cooperation